Atovaquone (DB01117): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Atovaquone is a hydroxynaphthoquinone antiprotozoal agent with a highly specific mechanism of action and a well-defined role in the management of several major infectious diseases. As a small molecule therapeutic, it functions as a potent and selective inhibitor of the mitochondrial electron transport chain in susceptible protozoa, primarily by targeting the cytochrome bc1 complex (Complex III). This action disrupts cellular respiration, leading to a collapse of the mitochondrial membrane potential and a subsequent shutdown of both adenosine triphosphate (ATP) and pyrimidine biosynthesis, processes essential for parasite survival and replication.

Clinically, Atovaquone is utilized in two principal contexts. As a standalone agent, marketed as Mepron®, it serves as a critical second-line therapy for the treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in patients who are intolerant to the standard-of-care agent, trimethoprim-sulfamethoxazole. Its utility is most pronounced in the fixed-dose combination with proguanil (Malarone®), a first-line agent for the prophylaxis and treatment of Plasmodium falciparum malaria, including strains resistant to other antimalarials. The synergistic interaction between Atovaquone and proguanil provides a powerful dual-pathway inhibition of parasite nucleic acid synthesis, enhancing efficacy and mitigating the development of resistance.

The therapeutic application of Atovaquone is fundamentally governed by its challenging physicochemical properties, namely its high lipophilicity and extremely low aqueous solubility. These characteristics result in low and variable oral bioavailability, a limitation that necessitates strict adherence to administration with a high-fat meal to ensure adequate absorption and clinical efficacy. This food effect is the single most important counseling point for patients and a critical factor in preventing treatment failure. Beyond its established indications, Atovaquone is the subject of intensive research for drug repurposing, with emerging evidence suggesting potential applications as a tumor hypoxia modifier in oncology and as a broad-spectrum antiviral agent.

Section 1: Chemical Identity and Physicochemical Properties

This section establishes the fundamental chemical and physical characteristics of Atovaquone. These properties, particularly its stereochemistry, lipophilicity, and solubility, are foundational to its biological activity, formulation, and pharmacokinetic profile.

1.1 Nomenclature and Identifiers

Atovaquone is a well-characterized small molecule drug with a comprehensive set of identifiers across various chemical and pharmacological databases.[1]

• Primary Name: Atovaquone [2]
• DrugBank ID: DB01117 [2]
• CAS Number: 95233-18-4 is the most commonly cited Chemical Abstracts Service registry number.[1] A secondary number, 94015-53-9, is also listed in some databases.[4]
• Chemical Names:
• The International Union of Pure and Applied Chemistry (IUPAC) name is 3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione.[4]
• A common systematic name that specifies the active stereoisomer is 2-[trans-4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione.[3] The designation of the trans- configuration is of paramount importance, as the spatial arrangement of the cyclohexyl ring relative to the naphthoquinone core is essential for biological activity. The cis-isomer is not therapeutically active, but it can be converted to the desired trans-isomer via acid-catalyzed epimerization, a critical step in ensuring the efficacy of the final drug product.[6]
• Synonyms and Developmental Codes: The drug is known by several brand names, including Mepron®, Wellvone®, and Acuvel®.[4] During its development, it was referred to by codes such as BW 566C, BW 556C-80, and 566C80.[1]
• Database Identifiers:
• PubChem CID: 74989 [4]
• ChEMBL ID: CHEMBL1450 [3]
• UNII (Unique Ingredient Identifier): Y883P1Z2LT [3]
• ATC (Anatomical Therapeutic Chemical) Code: P01AX06, classifying it as an antiprotozoal agent.[2]

1.2 Molecular Structure, Formula, and Weight

Atovaquone is structurally defined as a naphthoquinone derivative, a class of compounds to which it owes its biological activity.[4]

• Molecular Formula: C22​H19​ClO3​ [2]
• Molecular Weight: 366.84 g/mol [3]
• Chemical Structure: The molecule consists of a 1,4-naphthalenedione core. This core is substituted at the 2-position with a trans-4-(4-chlorophenyl)cyclohexyl group and at the 3-position with a hydroxyl group.[4] This structure confers a high degree of lipophilicity and makes it a structural analogue of ubiquinone (coenzyme Q10), the natural substrate for the mitochondrial enzyme it targets.[3]
• Structural Identifiers:
• InChIKey: BSJMWHQBCZFXBR-UHFFFAOYSA-N (non-stereospecific).[4] The stereospecific key for the active trans-isomer is KUCQYCKVKVOKAY-CTYIDZIISA-N.[3]
• SMILES: C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O (non-stereospecific).[4] The stereospecific SMILES string is OC=2C(=O)c1ccccc1C(=O)C=2[C@@H]3CC[C@H](CC3)c4ccc(Cl)cc4.[3]

1.3 Physical and Chemical Characteristics

The physicochemical properties of Atovaquone are the primary determinants of its pharmacokinetic challenges and formulation requirements. The combination of high lipophilicity and poor aqueous solubility is the central issue governing its clinical use.

• Appearance: A light yellow to brown crystalline powder.[9]
• Solubility: It is practically insoluble in water.[9] It exhibits slight solubility in acetone, insolubility in methanol, and is soluble up to 20 mM in dimethyl sulfoxide (DMSO).[9] This poor aqueous solubility is the rate-limiting step in its oral absorption, leading to significant pharmacokinetic variability and a pronounced food effect.
• Melting Point: The reported melting point ranges from 216 °C to 224 °C.[3]
• Purity: Pharmaceutical-grade Atovaquone typically has a purity of ≥98%, as verified by High-Performance Liquid Chromatography (HPLC).[5]
• Storage and Stability: Atovaquone is heat sensitive and should be stored at low temperatures, typically frozen at <0 °C or -20 °C for long-term stability.[9] Under appropriate conditions, it is stable for at least four years.[1]

Table 1: Key Chemical and Physical Properties of Atovaquone

Property	Value	Source(s)
IUPAC Name	3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione	4
CAS Number	95233-18-4	1
Molecular Formula	C22​H19​ClO3​	2
Molecular Weight	366.84 g/mol	3
Appearance	Light yellow to brown crystalline powder	9
Melting Point	216–224 °C	3
Aqueous Solubility	Practically insoluble	9
Organic Solvent Solubility	Slightly soluble in acetone; soluble in DMSO	9
Storage Conditions	Store frozen (<0 °C or -20 °C); heat sensitive	9

Section 2: Comprehensive Pharmacological Profile

The pharmacology of Atovaquone is characterized by its highly specific and potent action against parasitic mitochondria, which provides a therapeutic window that spares the host. Its clinical effectiveness is a direct result of this targeted mechanism, while its clinical application is dictated by a challenging pharmacokinetic profile.

2.1 Mechanism of Action: The Cytochrome bc1 Complex

Atovaquone's antiprotozoal activity stems from its function as a selective inhibitor of the mitochondrial electron transport chain, a pathway vital for parasite survival.[8]

• Primary Molecular Target: The primary site of action is the cytochrome bc1 complex, also known as Complex III, which is a critical component of the respiratory chain in protozoa.[1]
• Molecular Mimicry and Competitive Inhibition: Atovaquone is a structural analogue of the natural substrate ubiquinone (Coenzyme Q).[3] This mimicry allows it to bind with high affinity to the ubiquinol oxidation (Qo) site within the cytochrome bc1 complex, effectively acting as a competitive inhibitor and blocking the site from its natural substrate.[6] This binding is exceptionally potent against parasitic enzymes, with a half-maximal effective concentration ( EC50​) of approximately 0.95 nM in P. falciparum mitochondria, compared to 510 nM in rat liver mitochondria, a selectivity of over 500-fold that underpins its safety profile.[1]
• Functional Consequences of Inhibition: The blockade of the Qo site disrupts the transfer of electrons from ubiquinol to cytochrome c, triggering a cascade of catastrophic cellular events [14]:

1. Collapse of Mitochondrial Membrane Potential (ΔΨm​): Electron transport is coupled to the pumping of protons across the inner mitochondrial membrane, which establishes an electrochemical gradient known as the membrane potential. By halting electron flow, Atovaquone prevents proton pumping, leading to a rapid and irreversible collapse of this potential.[1] This effect has been directly observed in live parasites using flow cytometry assays.[18]
2. Inhibition of ATP Synthesis: The mitochondrial membrane potential is the primary driving force for ATP synthase. Its collapse starves the enzyme of energy, thereby halting the production of ATP and precipitating a cellular energy crisis.[8]
3. Indirect Inhibition of Pyrimidine Biosynthesis: In many protozoa, including Plasmodium, the mitochondrial electron transport chain serves a vital anabolic role in addition to energy production. The enzyme dihydroorotate dehydrogenase (DHODH), which catalyzes a key step in the de novo synthesis of pyrimidines (essential building blocks for DNA and RNA), is functionally linked to the respiratory chain. DHODH requires a continuous supply of oxidized ubiquinone as an electron acceptor to function.[6] By blocking the regeneration of ubiquinone at Complex III, Atovaquone indirectly but effectively shuts down DHODH activity. This disruption of nucleic acid synthesis is believed to be the ultimate lethal event for the parasite, preventing its replication and leading to cell death.[14] This multi-level failure—simultaneously cutting off energy supply and the production of genetic material—explains the drug's high potency.
4. Generation of Reactive Oxygen Species (ROS): The disruption of the electron transport chain can also lead to the leakage of electrons and the formation of superoxide and other reactive oxygen species. This induces a state of oxidative stress, causing damage to cellular components and contributing to parasite death.[14]

2.2 Synergistic Action with Proguanil

The combination of Atovaquone with proguanil in the product Malarone® is a classic example of pharmacologic synergy, designed to enhance efficacy and combat resistance.[20] The interaction is more complex than a simple additive effect.

Proguanil is a prodrug that is metabolized to its active form, cycloguanil. Cycloguanil inhibits a different critical enzyme in the same general pathway: dihydrofolate reductase (DHFR). DHFR is also essential for the synthesis of nucleic acid precursors.[13] This creates a dual blockade on pyrimidine and folate metabolism.

Counterintuitively, however, the prodrug proguanil itself possesses a unique synergistic activity. While proguanil has no direct inhibitory effect on electron transport, it acts as a "mitochondrial sensitiser." When used in combination, it significantly enhances the ability of Atovaquone to collapse the mitochondrial membrane potential, effectively lowering the concentration of Atovaquone needed to achieve its parasiticidal effect.[17] This elegant mechanism explains why the combination is successful even in regions where resistance to cycloguanil's DHFR-inhibiting action is prevalent.[18] This multi-target engagement—Atovaquone on Complex III, proguanil sensitizing Complex III, and cycloguanil on DHFR—presents a formidable barrier to the development of resistance and was a necessary evolution to overcome the high failure rates associated with Atovaquone monotherapy for malaria.[17]

2.3 Pharmacodynamics and Activity Spectrum

Atovaquone is a broad-spectrum antiprotozoal agent with activity against a range of medically important parasites.[1] Its spectrum includes:

• Plasmodium species: Active against both the blood stages (erythrocytic) and the liver stages (exoerythrocytic) of P. falciparum.[19]
• Pneumocystis jirovecii: The causative agent of PCP.[18]
• Toxoplasma gondii: The agent of toxoplasmosis.[1]
• Babesia species: Tick-borne protozoa that cause babesiosis.[1]

A key pharmacodynamic feature is its selective toxicity. The high degree of selectivity for the parasitic cytochrome bc1 complex over the mammalian homologue results in a favorable safety profile. Notably, it does not cause significant myelosuppression, making it a valuable therapeutic option for immunocompromised individuals, such as those with HIV or recipients of bone marrow transplants, who may not tolerate other antimicrobial agents.[8]

2.4 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The clinical use of Atovaquone is profoundly influenced by its pharmacokinetic profile, which is dominated by its poor aqueous solubility.

2.4.1 Absorption

Absorption of Atovaquone from the gastrointestinal tract is low, highly variable, and limited by its slow dissolution rate.[11]

• Critical Food Effect: Bioavailability is critically dependent on co-administration with food, particularly a meal containing fat. Food increases the rate and extent of absorption, elevating the area under the curve (AUC) by a factor of two to three and the maximum plasma concentration (Cmax​) by a factor of five compared to administration under fasting conditions.[19] This food effect is the most important clinical consideration for ensuring therapeutic efficacy.
• Bioavailability: The absolute bioavailability of the tablet formulation when taken with food is approximately 23%.[8] The oral suspension was developed to improve upon this, achieving a higher bioavailability of approximately 47% when taken with food.[8] This difference underscores the importance of formulation in overcoming the drug's inherent physicochemical limitations.

2.4.2 Distribution

Once absorbed, Atovaquone is widely distributed but remains largely within the plasma compartment due to extensive protein binding.

• Protein Binding: It is highly bound (>99.9%) to plasma proteins over a wide concentration range.[8]
• Volume of Distribution: The apparent volume of distribution (Vd​) is relatively small, reported as 0.60 L/kg.[8]

2.4.3 Metabolism

Atovaquone undergoes very limited metabolism. It is presumed to undergo enterohepatic cycling, which contributes to its long elimination half-life, but no specific metabolites have been identified.[8]

2.4.4 Excretion

The drug is eliminated almost exclusively via the feces.

• Primary Route: Over 94% of an administered dose is recovered as unchanged Atovaquone in the feces over a 21-day period.[11]
• Renal Excretion: Renal clearance is negligible, with less than 0.6% of the dose excreted in the urine.[11] This means that dose adjustments in renal impairment are generally not required for Atovaquone itself.
• Elimination Half-Life: The elimination half-life (t1/2​) is long, averaging 2 to 3 days in adults and 1 to 2 days in children.[8]

Table 2: Summary of Atovaquone Pharmacokinetic Parameters

Parameter	Value (Adults)	Key Considerations / Sources
Bioavailability (Fasting)	Low and variable; significantly sub-therapeutic	19
Bioavailability (With Food - Tablet)	~23%	8
Bioavailability (With Food - Suspension)	~47%	8
Effect of Food on Cmax​	~5-fold increase	19
Protein Binding	>99.9%	8
Volume of Distribution (Vd​)	0.60 L/kg	8
Metabolism	Limited; undergoes enterohepatic cycling	8
Primary Elimination Route	Fecal (>94% as unchanged drug)	11
Elimination Half-life (t1/2​)	2–3 days	19
Renal Excretion	<0.6%	11

Section 3: Clinical Applications and Efficacy

Atovaquone has carved out specific and important niches in the treatment of protozoal diseases. Its role is defined both by its spectrum of activity and by its position relative to other available therapies, often serving as an indispensable alternative for patients with contraindications to first-line agents.

3.1 Approved Indication: Pneumocystis jirovecii Pneumonia (PCP)

As a monotherapy (Mepron®), Atovaquone is FDA-approved for both the treatment and prevention of PCP, a life-threatening fungal infection common in immunocompromised individuals, particularly those with HIV/AIDS.[22]

• Place in Therapy: Atovaquone's role is not as a first-line agent but as a crucial alternative. The drug of choice for both treatment and prophylaxis of PCP remains trimethoprim-sulfamethoxazole (TMP-SMX) due to its superior efficacy.[26] Atovaquone is indicated specifically for patients who are intolerant to TMP-SMX, often due to hypersensitivity reactions or other toxicities.[22] This positioning as a therapy for the "intolerance niche" was central to its development and regulatory approval, which included an Orphan Drug Designation for the prevention of PCP in high-risk, HIV-infected patients.[27]
• Efficacy: For mild-to-moderate PCP, Atovaquone is an effective alternative, though clinical data suggest it is less active than TMP-SMX, with one source noting a higher treatment failure rate (17% for Atovaquone vs. 6% for TMP-SMX).[28]
• Limitations: The efficacy of Atovaquone has not been established in patients with severe PCP or in those who are failing therapy with TMP-SMX.[26] It is therefore not recommended for the management of severe disease.[3]

3.2 Approved Indication (in combination with Proguanil): Plasmodium falciparum Malaria

The fixed-dose combination of Atovaquone and Proguanil (Malarone®) is a cornerstone of modern malaria management. It is indicated for two primary uses:

1. Treatment of acute, uncomplicated P. falciparum malaria.[30]
2. Prophylaxis (prevention) of P. falciparum malaria.[30]

• Efficacy and Resistance: Malarone® has demonstrated high efficacy in clinical trials, with cure rates for treatment ranging from 87% to 100%.[32] It is particularly valuable because it remains effective in regions where resistance to older drugs like chloroquine and even mefloquine is widespread.[31] As a prophylactic agent, its success rate is exceptionally high, approaching 100% in controlled trials.[32] The development of this combination product was a clinical necessity. Atovaquone monotherapy for malaria, while initially potent, was plagued by unacceptable rates of treatment failure and recrudescence due to the rapid selection of resistant parasites.[17] The synergistic, multi-target mechanism of Malarone® provides a much higher barrier to resistance, salvaging the utility of Atovaquone for this critical indication.
• Limitations: Malarone® is not indicated for the treatment of severe or complicated malaria, such as cerebral malaria, for which parenteral therapy is required.[17] Furthermore, it is not active against the dormant liver stages (hypnozoites) of Plasmodium vivax and Plasmodium ovale. Therefore, when treating mixed infections or infections acquired in regions where these species are prevalent, Malarone® must be followed by a course of a hypnozoitocidal agent like primaquine to achieve a radical cure and prevent relapse.[20]

3.3 Significant Off-Label Applications

The broad-spectrum antiprotozoal activity of Atovaquone has led to its rational, mechanism-based use in other related infections, where it has become an important part of clinical practice guidelines.

• Babesiosis: Atovaquone, in combination with the macrolide antibiotic azithromycin, is a standard and recommended regimen for the treatment of babesiosis, a tick-borne parasitic disease.[2] Dosing guidelines for both adults and children are well-established.[29]
• Toxoplasmosis: For Toxoplasma gondii encephalitis, particularly in HIV-infected patients, Atovaquone serves as a valuable second-line therapy for individuals who cannot tolerate the first-line regimen of pyrimethamine and sulfadiazine.[2] It is used for both acute treatment and long-term suppressive therapy (secondary prophylaxis).[29]

3.4 Resistance Mechanisms and Clinical Implications

The primary mechanism of resistance to Atovaquone is well-understood and has significant clinical implications.

• Genetic Basis: Resistance arises from single point mutations in the mitochondrially encoded cytochrome b gene (cytb). These mutations occur within the Qo binding pocket, altering the amino acid sequence and reducing the binding affinity of Atovaquone to its target.[36] Specific mutations, such as those at codon 268 (e.g., Tyrosine to Serine, Y268S), have been definitively shown to confer high-level resistance in vivo.[17]
• Clinical Impact: The relative ease with which these resistance mutations can be selected under drug pressure is the reason Atovaquone monotherapy failed for malaria treatment.[17] This underscores the fundamental principle in infectious disease that combination therapy is often essential to prevent the emergence of resistance, a principle embodied by the success of Malarone®.

Section 4: Dosing, Administration, and Formulations

The effective and safe use of Atovaquone hinges on the correct selection of formulation, adherence to indication-specific dosing regimens, and strict observance of administration guidelines designed to overcome its pharmacokinetic limitations.

4.1 Available Formulations

Atovaquone is available in two distinct formulations, each tailored to different clinical applications. This divergence in formulation strategy reflects the different needs of the target patient populations: the flexible, high-dose suspension for treating PCP in often hospitalized, immunocompromised patients, and the convenient, fixed-dose tablet for malaria prophylaxis and treatment in travelers and outpatients.

• Atovaquone Oral Suspension (Mepron® and generics): This is a bright yellow, tutti-frutti flavored liquid formulation supplied at a standard concentration of 750 mg per 5 mL.[24] It is available in multi-dose bottles and 5 mL unit-dose foil sachets.[39] This formulation is used for PCP, babesiosis, and toxoplasmosis.
• Atovaquone/Proguanil HCl Tablets (Malarone® and generics): These are fixed-dose combination tablets for oral administration, available in two strengths for malaria [20]:
• Adult Strength: 250 mg Atovaquone with 100 mg Proguanil HCl.
• Pediatric Strength: 62.5 mg Atovaquone with 25 mg Proguanil HCl.

4.2 Detailed Dosing Regimens by Indication

Dosing for Atovaquone-containing products is highly specific to the indication, patient age, and body weight. The following table consolidates these complex guidelines into a practical reference.

Table 3: Dosing Regimens for Atovaquone-Containing Products

Indication	Patient Population	Formulation	Dosage Regimen	Duration	Key Notes
PCP Treatment	Adults & Adolescents (≥13 yrs)	Oral Suspension	750 mg (5 mL) PO BID	21 days	Must be taken with food. For mild-to-moderate disease only. 25
	Pediatrics (1 mo–12 yrs)	Oral Suspension	20 mg/kg PO BID	21 days	Max: 1500 mg/day. Must be taken with food. 29
PCP Prophylaxis	Adults & Adolescents (≥13 yrs)	Oral Suspension	1500 mg (10 mL) PO QD	Ongoing	Must be taken with food. 25
	Pediatrics (by age)	Oral Suspension	1–3 mo: 30 mg/kg QD 4–23 mo: 45 mg/kg QD 2–12 yrs: 30 mg/kg QD	Ongoing	Max: 1500 mg/day. Must be taken with food. 29
Malaria Treatment	Adults (>40 kg)	Adult Tablet	1 g / 400 mg (4 tablets) PO QD	3 days	Must be taken with food. 31
	Pediatrics (by weight)	Pediatric or Adult Tablets	5–8 kg: 125/50 mg (2 ped tabs) QD 9–10 kg: 187.5/75 mg (3 ped tabs) QD 11–20 kg: 250/100 mg (1 adult tab) QD 21–30 kg: 500/200 mg (2 adult tabs) QD 31–40 kg: 750/300 mg (3 adult tabs) QD	3 days	Must be taken with food. 20
Malaria Prophylaxis	Adults (>40 kg)	Adult Tablet	250 mg / 100 mg (1 tablet) PO QD	Pre-, during, and 7 days post-travel	Start 1–2 days before travel. Must be taken with food. 31
	Pediatrics (>11 kg, by weight)	Pediatric or Adult Tablets	11–20 kg: 62.5/25 mg (1 ped tab) QD 21–30 kg: 125/50 mg (2 ped tabs) QD 31–40 kg: 187.5/75 mg (3 ped tabs) QD >40 kg: 250/100 mg (1 adult tab) QD	Pre-, during, and 7 days post-travel	Start 1–2 days before travel. Must be taken with food. 20
Babesiosis (Off-Label)	Adults	Oral Suspension	750 mg PO BID with Azithromycin	7–10 days	Must be taken with food. 29
Toxoplasmosis (Off-Label)	Adults	Oral Suspension	750–1500 mg PO BID to QID	Weeks to months	Must be taken with food. Used with other agents. 28

4.3 Administration Guidelines and Patient Counseling

The administration guidelines for Atovaquone are not mere recommendations; they are direct countermeasures to the drug's inherent pharmacokinetic weaknesses and are essential for clinical success.

• Administration with Food: This is the single most critical instruction. All Atovaquone formulations must be administered with food or a milky drink. The high fat content of such a meal is required to facilitate the dissolution and absorption of the highly lipophilic drug. Failure to do so will result in sub-therapeutic plasma concentrations and a high risk of treatment failure.[19]
• Management of Vomiting: Due to the slow and variable nature of its absorption, vomiting shortly after administration can lead to loss of the dose. If a patient vomits within one hour of taking a dose, the dose should be repeated.[20]
• Patients with Dysphagia: For patients, particularly children, who have difficulty swallowing tablets, Malarone® tablets may be crushed and mixed with a small amount of condensed milk immediately before administration. This practice serves the dual purpose of easing administration and providing the fatty medium necessary for absorption.[20]
• Adherence: Patients should be counseled to take their dose at the same time each day to maintain consistent plasma levels and to complete the full prescribed course of therapy, even if symptoms improve, to ensure complete eradication of the pathogen and prevent relapse.[22]

4.4 Dosing in Special Populations

• Renal Impairment: The need for dose adjustment depends on the indication and the severity of impairment. The contraindication in severe renal impairment (Creatinine Clearance [CrCl] < 30 mL/min) is specifically for the long-term use of Atovaquone/Proguanil for malaria prophylaxis.[31] This is not driven by Atovaquone, which has negligible renal clearance, but by the risk of accumulation of its partner drug, proguanil, and its metabolite, which can lead to pancytopenia.[31] For short-term malaria treatment, the combination can be used with caution in severe renal impairment if the benefits are deemed to outweigh the risks.[31]
• Hepatic Impairment: No dose adjustments are required for patients with mild to moderate hepatic impairment. However, the drug should be used with caution and careful monitoring in patients with severe hepatic impairment.[23]
• Geriatric Population: No specific geriatric dose adjustments are recommended, but cautious dose selection is advised, accounting for the higher likelihood of decreased renal, hepatic, or cardiac function.[40]

Section 5: Safety, Tolerability, and Risk Management

Atovaquone is generally well-tolerated, particularly when compared to alternative agents for its indicated uses. However, a comprehensive understanding of its adverse effect profile, contraindications, and potential for drug interactions is essential for safe and effective clinical use.

5.1 Profile of Adverse Drug Reactions

The most frequently reported adverse effects associated with Atovaquone are gastrointestinal and neurological in nature.

• Common Adverse Events (≥5% incidence):
• Gastrointestinal: Nausea, vomiting, diarrhea, and abdominal pain are very common across all indications and patient populations.[22]
• Neurological: Headache and dizziness are frequently reported. Insomnia and unusual dreams have also been noted, particularly with prophylactic use of Malarone®.[22]
• General: Rash, fever, cough, and asthenia (weakness) are also common.[24]
• Serious and Postmarketing Adverse Events:
• Hepatobiliary Disorders: Elevations in liver function tests (e.g., ALT, AST) can occur.[24] While rare, serious hepatotoxicity has been reported, including cases of hepatitis, cholestasis, and fatal liver failure requiring transplantation. A definitive causal link has been difficult to establish in all cases due to confounding factors, but this remains a critical area for clinical vigilance.[24]
• Hypersensitivity Reactions: Maculopapular rash is a relatively common side effect.[24] Serious, though rare, hypersensitivity reactions have been reported, including angioedema, bronchospasm, vasculitis, and severe cutaneous adverse reactions such as erythema multiforme and Stevens-Johnson syndrome.[24]
• Hematologic Disorders: Rare cases of neutropenia, anemia, and thrombocytopenia have been reported.[24] Methemoglobinemia has been observed in the context of overdose, particularly when taken with other oxidizing agents like dapsone.[8] Pancytopenia is a specific risk for patients with severe renal impairment receiving proguanil.[40]

5.2 Contraindications, Warnings, and Precautions

While Atovaquone has a favorable safety profile, there are important contraindications and warnings that guide its use. A significant aspect of its safety profile is what is absent: unlike the antimalarial mefloquine, which carries an FDA black box warning for the risk of permanent neurological and psychiatric side effects, Atovaquone/Proguanil has no such warning.[43] This distinction is a major factor in its frequent selection as a first-line agent for malaria prophylaxis.

• Contraindications:

1. History of a serious hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to Atovaquone, proguanil, or any component of the formulation.[31]
2. Use of Atovaquone/Proguanil for malaria prophylaxis in patients with severe renal impairment (CrCl < 30 mL/min).[31]

• Warnings and Precautions:
• Gastrointestinal Disturbances: This represents a unique clinical challenge where a common side effect can directly undermine efficacy. Vomiting and diarrhea, common adverse effects of the drug, can significantly impair its absorption.[31] This creates a potential negative feedback loop where drug-induced GI intolerance leads to sub-therapeutic levels and treatment failure. Therefore, in patients with persistent vomiting or diarrhea, parasitemia must be closely monitored, and alternative therapy may be required.[31]
• Hepatotoxicity: Patients should be monitored for signs and symptoms of liver injury (e.g., jaundice, right upper quadrant pain, dark urine), and the drug should be used with caution in those with pre-existing severe hepatic impairment.[24]
• Severe Malaria: Atovaquone-containing products are not effective for and have not been evaluated in the treatment of severe or complicated malaria. Patients with manifestations such as cerebral malaria, pulmonary edema, or renal failure require parenteral antimalarial therapy.[31]

5.3 Management of Overdose

Experience with Atovaquone overdose is limited. Doses as high as 31,500 mg have been reported without lasting sequelae.[8] Reported symptoms of overdose include rash and, in one instance with concurrent dapsone, methemoglobinemia.[8] Other potential signs include headache, fatigue, and cyanosis.[22] Management is supportive.

5.4 Clinically Significant Drug-Drug and Drug-Food Interactions

Atovaquone's absorption and metabolism can be affected by co-administered substances.

• Drug-Food Interaction: The most important interaction is with food. Administration on an empty stomach drastically reduces absorption and must be avoided.[19]
• Drug-Drug Interactions: A summary of the most clinically significant interactions is provided in Table 4.

Table 4: Clinically Significant Drug Interactions with Atovaquone

Interacting Drug/Class	Effect on Atovaquone	Effect on Interacting Drug	Clinical Recommendation	Source(s)
Rifamycins (Rifampin, Rifabutin)	Plasma concentrations reduced by ~50%	N/A	Concomitant use is not recommended due to risk of therapeutic failure.	20
Metoclopramide	Decreased bioavailability	N/A	Use concomitantly only if other antiemetics are unavailable.	20
Tetracycline	Decreased plasma concentrations	N/A	Monitor parasitemia closely if used together.	20
Warfarin (and other coumarin anticoagulants)	No direct effect	Anticoagulant effect may be potentiated (proguanil component)	Monitor coagulation parameters (e.g., INR) closely when initiating or withdrawing therapy.	20
Certain Antiretrovirals (e.g., Efavirenz, Indinavir)	Decreased plasma concentrations	Trough concentrations of indinavir may be decreased	Use with caution and monitor for efficacy.	20

Section 6: Regulatory and Commercial Landscape

The regulatory and commercial history of Atovaquone illustrates a strategic lifecycle, beginning as a niche orphan drug and evolving into a widely used, globally important antimalarial agent that is now a mature product in a competitive generic market.

6.1 FDA Approval History and Key Milestones

The regulatory journey of Atovaquone can be viewed in two distinct acts: the initial approval of the monotherapy product, Mepron®, followed by the approval of the highly successful combination product, Malarone®.

• Act I: Mepron® (Atovaquone Monotherapy):
• The initial formulation, a 250 mg tablet, was approved by the FDA on November 25, 1992, for the treatment of PCP.[38] This tablet formulation has since been discontinued.
• Recognizing the bioavailability challenges, the improved 750 mg/5 mL oral suspension was approved on February 8, 1995.[38]
• The crucial indication for the prevention of PCP in patients intolerant to TMP-SMX was added on January 5, 1999.[27]
• Act II: Malarone® (Atovaquone/Proguanil Combination):
• The New Drug Application (NDA 21-078) for the fixed-dose combination was submitted by Glaxo Wellcome on December 29, 1998.[45]
• Malarone® was approved by the FDA on July 14, 2000, for both the treatment and prophylaxis of P. falciparum malaria. The approval included both the adult and pediatric strength tablets.[47]

Table 5: Summary of Key FDA Approval Milestones for Atovaquone-Containing Products

Product Name (Brand)	Active Ingredient(s)	Formulation	Manufacturer	NDA Number	Key Approval Date	Approved Indication
Mepron®	Atovaquone	Tablet, 250 mg	Glaxo Wellcome	020259	Nov 25, 1992	Treatment of PCP (Discontinued)
Mepron®	Atovaquone	Oral Suspension, 750 mg/5 mL	Glaxo Wellcome	020500	Feb 8, 1995	Treatment of PCP
Malarone®	Atovaquone / Proguanil HCl	Tablet, 250 mg / 100 mg	Glaxo Wellcome	021078	Jul 14, 2000	Treatment & Prophylaxis of Malaria
Malarone® Pediatric	Atovaquone / Proguanil HCl	Tablet, 62.5 mg / 25 mg	Glaxo Wellcome	021078	Jul 14, 2000	Treatment & Prophylaxis of Malaria

6.2 Orphan Drug Designation

A key element of Atovaquone's early development was its status as an orphan drug, which provided incentives for its development for a rare disease.

• Atovaquone was granted Orphan Drug Designation by the FDA on August 14, 1991.[27]
• The designated indication was the "Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients".[27]
• This designation led to a period of marketing exclusivity for this indication, which concluded on January 5, 2006, paving the way for future generic competition.[27]

6.3 Current Manufacturers and Generic Availability

Following the expiration of its patents, Atovaquone has transitioned from a proprietary product to a widely available generic medication.

• Original Developer: GlaxoSmithKline (GSK), the successor to Glaxo Wellcome, was the original developer and marketer of both Mepron® and Malarone®.[38]
• Generic Entry: The patent protection for Malarone® expired in 2013, with the first generic version approved in the US in 2011.[17]
• Current Landscape: The market for both Atovaquone oral suspension and Atovaquone/Proguanil tablets is now mature and highly competitive. The long list of approved generic manufacturers includes major companies such as Amneal Pharmaceuticals, Glenmark, Lupin Ltd, Mylan, and Teva, among others.[38] This robust generic competition has significantly increased access and lowered the cost of Atovaquone-based therapies, solidifying their place in global health.

Section 7: Emerging Research and Future Directions

While Atovaquone is a mature drug for its primary indications, ongoing research is actively exploring its potential for repurposing in other major therapeutic areas, primarily oncology and virology. This research leverages its core mechanism of mitochondrial inhibition to address new pathological processes.

7.1 Investigational Use in Oncology: A Hypoxia Modifier

A promising new application for Atovaquone is in oncology, not as a cytotoxic agent itself, but as a modulator of the tumor microenvironment.

• Scientific Rationale: Solid tumors often outgrow their blood supply, creating regions of low oxygen, or hypoxia. Tumor hypoxia is a major driver of cancer progression, metastasis, and resistance to therapy, particularly radiotherapy, which relies on oxygen to generate cytotoxic free radicals.[51] As a potent inhibitor of mitochondrial respiration, Atovaquone can significantly reduce the oxygen consumption rate of cancer cells. This action can reverse tumor hypoxia, re-oxygenating the tumor and potentially re-sensitizing it to conventional cancer treatments.[51]
• Key Clinical Trials:
• ATOM Trial: This completed window-of-opportunity study in patients with non-small cell lung cancer (NSCLC) provided the first clinical evidence that Atovaquone could successfully increase tumor oxygenation and suppress the expression of hypoxia-related genes.[52]
• ARCADIAN Trial: A subsequent Phase 1 trial combined Atovaquone with standard-of-care chemoradiotherapy in patients with locally advanced NSCLC. The trial successfully established a safe and tolerable dose (750 mg twice daily) and confirmed that the combination was feasible. Imaging studies in a subset of patients demonstrated an increase in tumor oxygen levels after Atovaquone treatment, and clinical outcomes were promising.[51] These results provide a strong foundation for larger, randomized trials to determine if this strategy improves patient outcomes.
• Ongoing Research: Active clinical trials are currently investigating Atovaquone's potential in other difficult-to-treat cancers, including platinum-resistant ovarian cancer and pediatric malignant brain tumors.[54]

7.2 Investigational Use in Virology

Atovaquone's indirect inhibition of pyrimidine synthesis provides a plausible mechanism for broad-spectrum antiviral activity, as many viruses, especially RNA viruses, are heavily dependent on the host cell's nucleotide pools for their rapid replication.

• SARS-CoV-2 (COVID-19): Initial in vitro studies showing that Atovaquone could inhibit SARS-CoV-2 replication spurred clinical investigation.[3] A randomized, placebo-controlled trial in hospitalized patients, however, yielded a nuanced result. The study's primary endpoint was negative; Atovaquone did not significantly enhance viral clearance for the overall study population.[56] This result serves as a critical lesson in drug repurposing: in vitro efficacy does not always translate to clinical success, often due to pharmacokinetic barriers. A deeper analysis of the trial data revealed a crucial pharmacodynamic relationship: there was a significant inverse correlation between Atovaquone plasma concentrations and SARS-CoV-2 viral load. Furthermore, drug levels were negatively correlated with patient BMI.[56] This suggests that Atovaquone may indeed possess antiviral activity, but the standard oral dose is insufficient to achieve therapeutic concentrations in many patients, particularly those with higher body weight. The trial did not disprove the drug's activity but rather highlighted that overcoming its poor bioavailability is the key hurdle to its potential use as an antiviral.
• Zika and Chikungunya Viruses: Preclinical research has shown that Atovaquone effectively inhibits the replication of both Zika virus (ZIKV) and Chikungunya virus (CHIKV) in human cell lines.[57] Crucially, it also inhibited ZIKV infection in an ex vivo human placental tissue model. This finding is particularly compelling because ZIKV is known to cause severe congenital birth defects, and there are very few antiviral drugs considered safe for use during pregnancy. Atovaquone's established safety record for malaria prophylaxis in pregnant women makes it a uniquely attractive candidate for development as a "pregnancy-acceptable" antiviral to protect against these and other emerging arboviral threats.[57]

7.3 Other Research Areas

Research continues to refine the use of Atovaquone in its established roles. A systematic review evaluated whether the standard 7-day post-travel course of Malarone® prophylaxis could be shortened. The analysis concluded that while some limited evidence suggests a shorter course might be effective, the short half-life of the proguanil component and the theoretical risk of selecting for Atovaquone-resistant parasites mean that the current 7-day recommendation should be maintained pending more definitive clinical data.[58]

Conclusion

Atovaquone (DB01117) is a hydroxynaphthoquinone antiprotozoal with a well-defined and highly selective mechanism of action targeting the mitochondrial cytochrome bc1 complex of susceptible pathogens. Its journey from an orphan drug for Pneumocystis jirovecii pneumonia to a component of a first-line antimalarial combination therapy illustrates a successful lifecycle management strategy, solidifying its importance in the global infectious disease armamentarium.

The clinical utility of Atovaquone is fundamentally shaped by a duality in its properties. Its potent, targeted mechanism provides a broad spectrum of activity against key protozoal pathogens—including Plasmodium, Pneumocystis, Toxoplasma, and Babesia—with a favorable safety profile that makes it a vital alternative for patients intolerant to standard therapies. Conversely, its challenging physicochemical characteristics, particularly its poor aqueous solubility, create a significant pharmacokinetic hurdle, resulting in low and variable oral bioavailability. This limitation mandates strict adherence to administration with fatty foods, a critical factor that dictates its clinical success or failure.

The development of the fixed-dose combination with proguanil (Malarone®) was a pivotal moment in the drug's history, creating a synergistic, multi-target agent that effectively overcame the challenge of rapidly emerging resistance to Atovaquone monotherapy. Today, as a widely available generic medication, Atovaquone remains a cornerstone of PCP management and malaria control.

Looking forward, the story of Atovaquone is entering a new chapter focused on drug repurposing. Its fundamental mechanism of mitochondrial inhibition is being cleverly exploited in oncology to reverse tumor hypoxia and sensitize cancers to radiotherapy, a novel strategy with promising early clinical data. In virology, its potential as a broad-spectrum, "pregnancy-acceptable" antiviral agent for pathogens like Zika virus represents a significant opportunity to address a major unmet medical need. However, the cautionary results from COVID-19 trials underscore that realizing this future potential will depend on developing innovative formulation or delivery strategies to overcome the same pharmacokinetic barriers that have defined its use for the past three decades.

Works cited

1. Atovaquone (BW 566C, BW 556C-80, CAS Number: 95233-18-4) | Cayman Chemical, accessed September 6, 2025, https://www.caymanchem.com/product/23802/atovaquone
2. Atovaquone - brand name list from Drugs.com, accessed September 6, 2025, https://www.drugs.com/ingredient/atovaquone.html
3. Atovaquone - Wikipedia, accessed September 6, 2025, https://en.wikipedia.org/wiki/Atovaquone
4. 3-(4-(4-Chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dione | C22H19ClO3 | CID 74989 - PubChem, accessed September 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/74989
5. Atovaquone | CAS 95233-18-4 - Tocris Bioscience, accessed September 6, 2025, https://www.tocris.com/products/atovaquone_6358
6. Antimalarial pharmacology and therapeutics of atovaquone - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4344550/
7. Atovaquone - PubChem, accessed September 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Atovaquone
8. Atovaquone: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 6, 2025, https://go.drugbank.com/drugs/DB01117
9. Atovaquone 95233-18-4 | TCI AMERICA - Tokyo Chemical Industry, accessed September 6, 2025, https://www.tcichemicals.com/US/en/p/A2545
10. Atovaquone 95233-18-4 | Tokyo Chemical Industry (India) Pvt. Ltd., accessed September 6, 2025, https://www.tcichemicals.com/IN/en/p/A2545
11. 21-078 Malarone Clinical Pharmacology Biopharmaceutics Review - accessdata.fda.gov, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-078_malarone_biopharmr.pdf
12. Atovaquone (CAS 95233-18-4) - R&D Systems, accessed September 6, 2025, https://www.rndsystems.com/products/atovaquone_6358
13. MALARONE MALARONE - accessdata.fda.gov, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021078s014lbl.pdf
14. What is the mechanism of Atovaquone? - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-atovaquone
15. pmc.ncbi.nlm.nih.gov, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4344550/#:~:text=Mode%20of%20action,at%20the%20bc1%20complex.
16. Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1 | PNAS, accessed September 6, 2025, https://www.pnas.org/doi/10.1073/pnas.1416611112
17. Atovaquone/proguanil - Wikipedia, accessed September 6, 2025, https://en.wikipedia.org/wiki/Atovaquone/proguanil
18. A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil | Antimicrobial Agents and Chemotherapy - ASM Journals - American Society for Microbiology, accessed September 6, 2025, https://journals.asm.org/doi/10.1128/aac.43.6.1334
19. MALARONE MALARONE - accessdata.fda.gov, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021078s016lbl.pdf
20. Atovaquone/Proguanil Monograph for Professionals - Drugs.com, accessed September 6, 2025, https://www.drugs.com/monograph/atovaquone-proguanil.html
21. Antiparasitic Agent Atovaquone - PMC - PubMed Central, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC127192/
22. Atovaquone: MedlinePlus Drug Information, accessed September 6, 2025, https://medlineplus.gov/druginfo/meds/a693003.html
23. Clinical Pharmacology of Atovaquone and Proguanil Hydrochloride - Oxford Academic, accessed September 6, 2025, https://academic.oup.com/jtm/article/6/S1/S13/7179514
24. Mepron (atovaquone) dosing, indications, interactions, adverse effects, and more, accessed September 6, 2025, https://reference.medscape.com/drug/mepron-atovaquone-342686
25. Atovaquone (oral route) - Side effects & dosage - Mayo Clinic, accessed September 6, 2025, https://www.mayoclinic.org/drugs-supplements/atovaquone-oral-route/description/drg-20062055
26. Atovaquone Monograph for Professionals - Drugs.com, accessed September 6, 2025, https://www.drugs.com/monograph/atovaquone.html
27. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed September 6, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=48990
28. Atovaquone - FPnotebook, accessed September 6, 2025, https://fpnotebook.com/ID/Pharm/Atvqn.htm
29. Atovaquone Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed September 6, 2025, https://www.drugs.com/dosage/atovaquone.html
30. Atovaquone and Proguanil: MedlinePlus Drug Information, accessed September 6, 2025, https://medlineplus.gov/druginfo/meds/a619023.html
31. MALARONE (atovaquone and proguanil hydrochloride) tablets - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021078s023lbl.pdf
32. Atovaquone-proguanil for prophylaxis and treatment of malaria - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/12921511/
33. 21-078 Malarone Medical Review Part 3 - accessdata.fda.gov, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-078_Malarone_Medr_P3.pdf
34. "Randomized, Placebo-Controlled Trial of Atovaquone/Proguanil for the " by Judith Ling, J. Kevin Baird et al. - UNL Digital Commons - University of Nebraska–Lincoln, accessed September 6, 2025, https://digitalcommons.unl.edu/usnavyresearch/80/
35. atovaquone (Mepron) - International Association of Providers of AIDS Care, accessed September 6, 2025, https://www.iapac.org/fact-sheet/atovaquone-mepron/
36. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/10447880/
37. Understanding the Mechanism of Atovaquone Drug Resistance in Plasmodium falciparum Cytochrome b Mutation Y268S Using Computational Methods | PLOS One - Research journals, accessed September 6, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110041
38. Generic Mepron Availability - Drugs.com, accessed September 6, 2025, https://www.drugs.com/availability/generic-mepron.html
39. Atovaquone Oral Suspension USP - Glenmark Pharmaceuticals Inc., accessed September 6, 2025, https://glenmarkpharma-us.com/atovaquone-oral-suspension-usp/
40. Malarone, (atovaquone-proguanil) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed September 6, 2025, https://reference.medscape.com/drug/malarone-atovaquone-proguanil-342697
41. Atovaquone and proguanil (oral route) - Side effects & dosage - Mayo Clinic, accessed September 6, 2025, https://www.mayoclinic.org/drugs-supplements/atovaquone-and-proguanil-oral-route/description/drg-20061484
42. Dosing Recommendations for Prevention and Treatment of Malaria - Clinical Info HIV.gov, accessed September 6, 2025, https://clinicalinfo.hiv.gov/en/table/dosing-recommendations-prevention-and-treatment-malaria
43. Mefloquine (Lariam®) - VA Public Health, accessed September 6, 2025, https://www.publichealth.va.gov/exposures/mefloquine-lariam.asp
44. An anti-malaria drug may have inflicted permanent neurological injuries on some servicemembers | The American Legion, accessed September 6, 2025, https://www.legion.org/information-center/news/magazine/2019/july/an-anti-malaria-drug-may-have-inflicted-permanent-neurological-injuries-on-some-servicemembers
45. 21-078 Malarone Medical Review Part 1 - accessdata.fda.gov, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-078_Malarone_Medr_P1.pdf
46. Drug Approval Package: Mepron (Atovaquone) NDA# 20-500/S-005 - accessdata.fda.gov, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020500S005.cfm
47. Generic Malarone Pediatric Availability - Drugs.com, accessed September 6, 2025, https://www.drugs.com/availability/generic-malarone-pediatric.html
48. Drug Approval Package: Malarone (atovaquone and proguaril hydrochloride) NDA #021078, accessed September 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/021078_malarone.cfm
49. Atovaquone/Proguanil - Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis - NCBI, accessed September 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK556585/
50. Generic ATOVAQUONE INN entry, pharmaceutical patent and freedom to operate - DrugPatentWatch, accessed September 6, 2025, https://www.drugpatentwatch.com/p/generic/ATOVAQUONE
51. A trial of atovaquone with chemotherapy and radiotherapy for non small cell lung cancer (ARCADIAN), accessed September 6, 2025, https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-atovaquone-with-chemotherapy-and-radiotherapy-for-non-small-cell-lung-cancer-arcadian
52. ATOM: Atovaquone as Tumour HypOxia Modifier - Department of Oncology, accessed September 6, 2025, https://www.oncology.ox.ac.uk/research/clinical-trials/oncology-clinical-trials-office-octo/completed-trials/ATOM
53. ARCADIAN: Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC, accessed September 6, 2025, https://www.oncology.ox.ac.uk/research/clinical-trials/oncology-clinical-trials-office-octo/completed-trials/arcadian-atovaquone-with-radical-chemoradiotherapy-in-locally-advanced-nsclc
54. High Grade Gliomas Recruiting Phase 1 Trials for Atovaquone, accessed September 6, 2025, https://go.drugbank.com/indications/DBCOND0034320/clinical_trials/DB01117?phase=1&status=recruiting
55. Clinical Trials Using Atovaquone - NCI, accessed September 6, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/atovaquone?pn=1
56. Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9561237/
57. Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6532098/
58. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review - PubMed Central, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10956543/
59. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/29242073/